# The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

> **NCT05220410** · PHASE2 · COMPLETED · sponsor: **Sheppard Pratt Health System** · enrollment: 20 (actual)

## Conditions studied

- Treatment Resistant Depression
- Suicidal Ideation

## Interventions

- **DRUG:** Psilocybin

## Key facts

- **NCT ID:** NCT05220410
- **Lead sponsor:** Sheppard Pratt Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-28
- **Primary completion:** 2025-05-12
- **Final completion:** 2025-05-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05220410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05220410, "The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05220410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*